Q Fever Market Driven by Growing Prevalence of Bacterial Diseases

Market Overview:

Q fever is a bacterial disease caused by the Coxiella burnetii bacterium. It usually manifests in flu-like symptoms and is fairly easy to treat. However, in a small percentage of patients, Q fever may present as a chronic disease. This chronic version of the disease can be much more dangerous, with potential implications for the patient’s cardiovascular system and the possible contraction of pneumonia, hepatitis, and encephalitis. The chronic version of Q fever is thus more feared and is the reason why considerable expenses have been made to counter the condition.

The global Q Fever Market is expected to exhibit a strong 7.83% CAGR over the forecast period from 2018 to 2023, according to the latest research report from Market Research Future (MRFR). The global Q fever market is thoroughly analyzed in the report in order to provide readers with a complete overview of the market’s major drivers and restraining factors, as well as the economic background of the market and the competitive landscape of the market. The global Q fever market is expected to reach a valuation of more than USD 6.2 million by 2023.

The increasing prevalence of bacterial and other infectious diseases is likely to be the major driver for the global Q fever market over the forecast period, as this has led to considerable research expenditure on eradicating these diseases. Contagious diseases are being researched in a number of ways around the world, with researchers looking to minimize the risk of contracting such diseases as well as ways of countering the diseases once contracted. This is likely to be a major driver for the global Q fever market over the forecast period.

Competitive Analysis:

·         AtoxBio

·         Yashica Pharmaceuticals

·         Johnson & Johnson Services Inc

·         Bayer AG

·         Melinta Therapeutics Inc

·         Sanofi SA

·         Basilea Pharmaceutica Ltd

·         Pfizer Inc

·         Teva Pharmaceutical

·         Merck KGaA

Segmentation:

·         The global Q fever market is segmented on the basis of type, diagnosis, treatment, end use, and region.

·         By type, the global Q fever market is segmented into acute and chronic. The chronic Q fever segment is the leading revenue generator and is likely to exhibit the higher CAGR over the forecast period.

·         By diagnosis, the Q fever market is segmented into serology tests and others.

·         By treatment, the global Q fever market is segmented into antibiotics and surgery. Surgery dominates the global Q fever market by treatment type, as it is a crucial accessory to treating chronic Q fever, where the damage may have spread to other organ systems in the body.

·         By end use, the global Q fever market is segmented into patients, hospitals and clinics, and others. The patients segment held a dominant share of more than 72% in the global Q fever market in 2017.

Regional Analysis:

Asia Pacific is the leading regional market in the global Q fever market, and holds a share of 44.5% in the market as of 2017. The region is also expected to exhibit the highest CAGR over the forecast period, of 8.57%. Europe followed Asia Pacific in the global Q fever market in 2017, followed by the Middle East and Africa.